Akebia

AKBA NASDAQ
4.260
-0.160
-3.62%
已收盘, 17:55 06/24 EDT
开盘
4.410
昨收
4.420
最高
4.480
最低
4.220
成交量
127.25万
成交均量(3M)
115.01万
52周最高
11.32
52周最低
4.090
换手率
1.08%
市值
5.02亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Akebia AKBA股票价格,Akebia股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
展开 >

最近浏览

名称
价格
涨跌幅